Teaming up with Eric Lefkofsky in Fighting Cancer

Posted by under Cancer, Research

Eric Lefkofsky is among the top most prominent entrepreneurs in Chicago. He is widely known for donating hundreds of dollars to support research activities about cancer. Supporting and creating charitable organizations is a clear indication that he has positively impacted the lives of many. In his journey of helping to control cancer, becoming the Co-founder of Tempus is evidently one of the greatest hallmarks.

Born on September 2, 1969 in Michigan, USA, Eric Lefkofsky completed Law School from the University of Michigan. He had a humble start in life, selling carpets at the university to earn a living. Despite this, he currently has a net worth of more than 2.2 billion US dollars. As the old saying goes, hard work yields fruits. Besides being the co-founder, he is also the Chief Executive Officer at Tempus Company.

Huge Investment by Eric to Fight Cancer

Let’s talk about this Tempus. Tempus is a health tech company which has created infrastructure to provide a modernized approach in battling cancer. They help doctors and therapists understand better the tumor developing on their specific patient. By educating the doctors on the genomic codes of their patients by analyzing large volumes of genomic data, the patients are able to get better by receiving personalized treatment.

Understanding Prior Cancer

In the US, most patients diagnosed with cancer have survived prior cancer, and unfortunately, excluded from clinical observation or trials since their treatment and survival needs are not known. Understanding the nature of prior cancer is crucial in improving the patient’s health. Understanding the human molecular map has been made possible through genome sequencing. This is behind the personalized treatment of cancer patients in Tempus by intensely studying their tumors.

With the cancer surviving population growing gradually, it is critical to understand the impact and nature of prior cancer. This improves the trial accrual and the accuracy of the study of trial results, disease outcome, observational studies, and patient experience.

To Know More Click Here

Leave a Reply

Your email address will not be published. Required fields are marked *